ArticleClinical journal of the American Society of Nephrology : CJASN2015
Lifetime Risk of Stage 3-5 CKD in a Community-Based Sample in Iceland.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of targeted screening for chronic kidney disease in the community setting: a systematic review.Journal of nephrology · 2018Pooled it
- HIV associated epigenetic trends and chronic diseases: insights into the hidden burden of chronic infection.Clinical epigenetics · 2026Review
- Efficacy and safety of esaxerenone in hypertensive patients with chronic kidney disease, with or without type 2 diabetes mellitus: a pooled analysis of five clinical studies.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Current use of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors for hypertension in patients with chronic kidney disease with proteinuria: a cross-sectional study based on real-world data.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Risk of incident chronic kidney disease among patients with urolithiasis: a nationwide longitudinal cohort study.Clinical kidney journal · 2024Article
- Lifetime risk of severe kidney disease in lithium-treated patients: a retrospective study.International journal of bipolar disorders · 2023Article
- Effects of a High-Protein Diet on Kidney Injury under Conditions of Non-CKD or CKD in Mice.International journal of molecular sciences · 2023Article
- Global, regional, and national burden of chronic kidney disease attributable to high sodium intake from 1990 to 2019.Frontiers in nutrition · 2023Article
- Benchmarking CKD: incidence of CKD in a European country with low prevalence of CKD and kidney replacement therapy.Clinical kidney journal · 2022Article
- Preoperative renal function affects outcomes of surgery for aortic arch aneurysm in the elderly.General thoracic and cardiovascular surgery · 2021Article
- Identification of Patients with CKD in Medical Databases: A Comparison of Different Algorithms.Clinical journal of the American Society of Nephrology : CJASN · 2021Article
- Cause-specific mortality in the general population with transient dipstick-proteinuria.PloS one · 2019Article
- Survivability of hospitalized chronic kidney disease (CKD) patients with moderate to severe estimated glomerular filtration rate (eGFR) after experiencing adverse drug reactions (ADRs) in a public healthcare center: a retrospective 3 year study.BMC pharmacology & toxicology · 2018Observational
- Residual lifetime risk of chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2017Article
- Epidemiology of chronic kidney disease: think (at least) twice!Clinical kidney journal · 2017Article
- An Age-Calibrated Definition of Chronic Kidney Disease: Rationale and Benefits.The Clinical biochemist. Reviews · 2016Article
- Lifetime Risk of CKD: What Does It Really Mean?Clinical journal of the American Society of Nephrology : CJASN · 2015Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
objectivesLifetime risk estimates of CKD can be used effectively in public education campaigns. This study sought to estimate lifetime risk of incident CKD stage 3 and higher in Iceland for people without CKD by the age of 45 years. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a prospective cohort study with longitudinal creatinine measurements of residents in Reykjavik, Iceland, from 1967 to 2005. CKD was ascertained by two consecutive eGFR measurements <60 ml/min per 1.73 m(2), development of treated kidney failure, one eGFR<60 ml/min per 1.73 m(2) if the participant died before the next evaluation, or one eGFR<45 ml/min per 1.73 m(2) if it was the last eGFR.
resultsMean follow-up was 25 (SD 10) years. Of the study participants, 727 (19%) developed the outcome and 942 (24%) died first. By age 85 years, the lifetime risks for 45-year-old women and men without prevalent CKD were 35.8% (95% confidence interval [95% CI], 32.7 to 38.9) and 21.3% (95% CI, 18.7 to 23.8), respectively. Risk was higher in individuals with a lower eGFR, hypertension, and a higher body mass index. Lifetime risk for higher stages of CKD 3b and 4 were less common than stage 3a; by age 85 years, the lifetime risks for CKD stages 3a, 3b, and 4 in women were 38.5% (95% CI, 25.8 to 51.1), 19.4% (95% CI, 8.9 to 29.9), and 3.6% (95% CI, 2.2 to 5.0), respectively.
conclusionsThe lifetime risk of developing CKD stage 3 or higher is substantial, emphasizing the importance of strategies to prevent development of CKD throughout the course of life. Estimates are lower than reported using single estimates of GFR, emphasizing the importance of confirming estimates of reduced GFR in studies of CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.